Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (451-460 of 688) with videos related to

Pageof 69
Sort By:
Circulation. Heart Failure|April 9, 2016
Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection FractionAngela B S Santos, Gabriela Querejeta Roca, Brian Claggett, et al.
Circulation. Heart Failure|January 21, 2020
Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository StudyPeder L Myhre, Muthiah Vaduganathan, Eileen O'Meara, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|August 31, 2017
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER StudyJoão Pedro Ferreira, Kévin Duarte, Gilles Montalescot, et al.
JACC. Heart Failure|April 1, 2017
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT TrialInder S Anand, Brian Claggett, Jiankang Liu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 18, 2017
A Randomized Crossover Trial of Dietary Sodium Restriction in Stage 3-4 CKDRajiv Saran, Robin L Padilla, Brenda W Gillespie, et al.
International Journal of Cardiology|January 20, 2012
Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trialC Barrett Bowling, Paul W Sanders, Richard M Allman, et al.
Kidney International|November 11, 2022
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetesGeorge L Bakris, Luis M Ruilope, Stefan D Anker, et al.
European Journal of Heart Failure|December 10, 2024
Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fractionLuca Monzo, Emmanuel Bresso, Kenneth Dickstein, et al.
American Journal of Hypertension|August 8, 2023
What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of EvidenceKaja Sevre, Aurora Rist, Kristian Wachtell, et al.
Lancet (London, England)|February 23, 2010
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trialGeorge L Bakris, Pantelis A Sarafidis, Matthew R Weir, et al.
Pageof 69

Showing results (451-460 of 688) with videos related to

Sort By:
Pageof 69
Circulation. Heart Failure|April 9, 2016
Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection FractionAngela B S Santos, Gabriela Querejeta Roca, Brian Claggett, et al.
Circulation. Heart Failure|January 21, 2020
Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository StudyPeder L Myhre, Muthiah Vaduganathan, Eileen O'Meara, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|August 31, 2017
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER StudyJoão Pedro Ferreira, Kévin Duarte, Gilles Montalescot, et al.
JACC. Heart Failure|April 1, 2017
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT TrialInder S Anand, Brian Claggett, Jiankang Liu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 18, 2017
A Randomized Crossover Trial of Dietary Sodium Restriction in Stage 3-4 CKDRajiv Saran, Robin L Padilla, Brenda W Gillespie, et al.
International Journal of Cardiology|January 20, 2012
Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trialC Barrett Bowling, Paul W Sanders, Richard M Allman, et al.
Kidney International|November 11, 2022
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetesGeorge L Bakris, Luis M Ruilope, Stefan D Anker, et al.
European Journal of Heart Failure|December 10, 2024
Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fractionLuca Monzo, Emmanuel Bresso, Kenneth Dickstein, et al.
American Journal of Hypertension|August 8, 2023
What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of EvidenceKaja Sevre, Aurora Rist, Kristian Wachtell, et al.
Lancet (London, England)|February 23, 2010
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trialGeorge L Bakris, Pantelis A Sarafidis, Matthew R Weir, et al.
Pageof 69